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Cisplatin (cisPt)-resistance poses a major clinical problem in the
treatment of non-small cell lung cancer (NSCLC).1, 2 However, the
mechanisms accounting for metabolic adaptations in cisPt-resistant cells
are not well understood. In cultured NSCLC cells with induced cisPt
resistance a long-term resistance is retained after de-induction.3 High
resolution magic angle spinning (HR-MAS) NMR spectroscopy allows to
metabolically characterize biological samples like cells or tissue.4-6
A24 0.5 μM 2.0 μM 4.0 μM 8.0 μM
cisplatin (cisPt) concentration in medium
A24 D-Pt2.0A24 D-Pt0.5 A24 D-Pt4.0 A24 D-Pt8.0
A24-0a
A24 Pt0.5 A24 Pt2 A24 Pt4 A24 Pt8A24-0b
METHODS
cisPt-resistant cell lines
 Generated from cisPt-sensitive WT-lung adenocarcinoma cells (A24)3
 Exposure to stepwise increasing concentrations of cisPt in the culture
medium ranging from 0.5μM to 8μM (Fig.1)
 For de-induction cells branched off and grown in the absence of cisPt
A24 cells/sublines
cultured (RPMI 1640)





500 MHz, 3kHz MAS, T=276K
1D-PROJECT7, TE=400 ms, ns=512
water-presaturation




2 x 15 Fig. 2: 1D PROJECT spectrum (excerpt for 0.5-3.5 ppm spectral region)
More than 50 metabolites were assigned including:
Amino acids, peptides, organic acids, amines, choline containing 
compounds, nucleobases, nucleosides, nucleotides, phosphate sugars 
and lipids
AIMS
 Systematically investigate metabolic alterations in cultured NSCLC-
cells with incremented induced and de-induced cisPt-resistance
 Apply HR-MAS NMR-based metabolomics to study the metabolome
using cisPt-sensitive NSCLC-cells (A240286S, A24) as controls
 Identify A24 cell metabolites and potential markers of cisPt-resistance
 Address the question if the maintenance of cisPt-resistance in de-
























































































































































 Spectra subdivided into 309 individually sized buckets
 Probabalistic quotient normalization; mean centering, pareto scaling
 Principal Component Ananlysis (PCA) and orthogonal Partial least
squares analysis (o-PLS) unsing PLS-Toolbox (Eigenvector)
Fig. 3A: Unsupervised PCA on all samples (30 x 309) demonstrates:
 Close clustering of replicates
 Scores along PC-2 correlate with increasing cisPt resistance
 De-induced samples are close to their induced counterparts
 Clear separation of the two batches along PC-1 (possibly due to 
passage and media differences) 
 cisPt resistance is reflected in metabolic alterations
 GSH and Tau may serve as biomarkers with elevated 
levels in cisPt resistant cells
 GSH and Tau may function as reactive oxygen species 
scavenger and for cellular defense (anitapoptotic)8,9
 Developed cisPt-resistance is an adaptation that is 
maintained even after cisPt removal and indicates a 
metabolic long-term memory of the cells  
Fig. 1














































Fig. 3B: oPLS on all samples (30 x 309) demonstrates:
 Close clustering of replicates
 Scores along LV-1 correlate with increasing cisPt resistance
 De-induced samples are metabolically similar to their induced 
counterparts
 Batches separate along LV-2
Fig. 3C: PLS model prediction performs very well
 For all samples, the predicted resistance is close to the measured one
Fig. 3D: Loading plot for oPLS LV-1
 Glutathione (GSH) and taurine (Tau) increased in cisPt-resistant cells
 Creatine (Cr) and Phosphocholine (PC) appear reduced
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